Screener
Nektar Therapeutics NKTR Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Fair Value Hierarchy Level | March 31, 2026 / Amortized Cost | March 31, 2026 / Gross Unrealized Gains | March 31, 2026 / Gross Unrealized Losses | March 31, 2026 / Fair Value | December 31, 2025 / Fair Value |
|---|---|---|---|---|---|---|
| Corporate notes and bonds | 2 | $288,887 | $2 | $(723) | $288,166 | $59,785 |
| Corporate commercial paper | 2 | 401,816 | 1 | (307) | 401,510 | 156,714 |
| Obligations of U.S. government agencies | 2 | 4,490 | — | (7) | 4,483 | — |
| Available-for-sale investments | $695,193 | $3 | $(1,037) | $694,159 | $216,499 | |
| Money market funds | 1 | 17,710 | 11,919 | |||
| Certificates of deposit | 2 | 14,029 | 14,138 | |||
| Cash | N/A | 5,699 | 3,196 | |||
| Total cash and investments in marketable securities | $731,597 | $245,752 |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's unrealized losses on investments (before tax)?
- Nektar Therapeutics (NKTR) reported unrealized losses on investments (before tax) of $1.04M in Q1 2026.
- How has Nektar Therapeutics's unrealized losses on investments (before tax) changed year-over-year?
- Nektar Therapeutics's unrealized losses on investments (before tax) increased by 2311.6% year-over-year, from $43K to $1.04M.
- What is the long-term trend for Nektar Therapeutics's unrealized losses on investments (before tax)?
- Over 2 years (2020 to 2022), Nektar Therapeutics's unrealized losses on investments (before tax) has grown at a 200.0% compound annual growth rate (CAGR), from $200K to $1.8M.
Ask your AI about Nektar Therapeutics's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude